The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Three lines of targeted therapy for metastatic renal cell carcinoma (mRCC): A viable strategy?
Tomas Buchler
Honoraria - Bayer; Pfizer
Zbynek Bortlicek
No relevant relationships to disclose
Alexandr Poprach
No relevant relationships to disclose
Katerina Kubackova
Honoraria - Novartis
Other Remuneration - Novartis
Igor Kiss
Consultant or Advisory Role - Bayer
Milada Zemanova
No relevant relationships to disclose
Ondrej Fiala
No relevant relationships to disclose
Jitka Abrahamova
No relevant relationships to disclose
Bohuslav Melichar
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis